SOURCE: Clearant, Inc.

October 12, 2007 09:00 ET

Clearant, Inc. Announces Its Attendance at FDA Allograft Conference

LOS ANGELES, CA--(Marketwire - October 12, 2007) - Clearant, Inc. (OTCBB: CLRA) is attending the FDA sponsored workshop on the Processing of Orthopedic, Cardiovascular, and Skin Allografts in Bethesda, Maryland on October 11th and 12th, 2007.

The workshop and public meeting is being organized by the FDA to discuss the topics of current surgeon clinical practices of allografts, pre/post processing cultures for microorganisms, challenges and concerns with existing culture methods, and disinfection and sterilization of tissues pre-allograft.

This sponsored workshop is the result of the formation of the Human Tissue Task Force (HTTF). The HTTF was created by the FDA in August of 2006 in response to increasing concerns regarding the safety of cadaver material used for allografts. This concern culminated due to two nationally reported incidents of improper tissue handling, which resulted in the use of possibly contaminated tissues in many medical procedures. Clearant has a validated process for achieving a terminal sterility assurance level of 10(-6), which is the same level required of medical devices used for healthcare.

The workshop is sponsored by the FDA's Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), Office of Regulatory Affairs and the Centers for Disease Control and Prevention. For an Agenda of the workshop please see

About Clearant, Inc.:

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. For more information, please visit

Forward-Looking Statements:

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at

Contact Information

  • Contact:
    Clearant, Inc.
    Jon Garfield
    Chief Executive Officer